A Phase II Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Cancer, Pancreatic Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | July 2010 |
| End Date: | June 2012 |
A phase II study combining pertuzumab with erlotinib for patients with gemcitabine
refractory pancreatic adenocarcinoma
A single-institution, single-arm phase II study investigating pertuzumab and erlotinib as a
palliative regimen in the treatment of locally-advanced or metastatic pancreatic
adenocarcinoma. To qualify for the trial, patients will require prior treatment with and
disease progression through gemcitabine. Pertuzumab infusion will be administered every 21
days, while erlotinib tablets will be taken daily. Patients will receive CT scans at
baseline and prior to every 3rd cycle.
We found this trial at
1
site
Stanford university Hospital and Clinics Throughout our history, we have pioneered medical advances that save...
Click here to add this to my saved trials
